The Mobility Dividend: How a Cell-Free Biologic Could Redefine Human Longevity

IRVINE, Calif. – October 13, 2026 – For decades, the biotechnology sector has approached the concept of human longevity with a myopic focus on chronological lifespan. The prevailing narrative suggested that adding years to life was the ultimate medical triumph. Yet, as global populations age at an unprecedented rate, a stark reality has emerged: living longer is an economic and social liability if those additional years are defined by frailty, immobility, and a loss of independence. The paradigm is now shifting rapidly from lifespan to healthspan, and the race to preserve human mobility has become one of the most consequential frontiers in modern medicine.

This shift is currently taking center stage in Washington, D.C., where the U.S. National Academy of Medicine (NAM) is preparing to conclude its ambitious, seven-year Healthy Longevity Global Competition. Next week, on October 20, the initiative will culminate at the Healthy Longevity Global Innovator Summit, awarding a $1.5 million Grand Prize to a project demonstrating the greatest potential to impact healthy human aging. Among the select semifinalists vying for this prize is Immunis, Inc., an Irvine-based clinical-stage biotechnology company that is challenging conventional pharmacological approaches to muscle preservation.

Chosen from an initial, highly competitive pool of 720 Catalyst Award recipients spanning more than 50 countries, the company’s advancement to the Grand Prize phase represents more than just a corporate milestone. It signals a growing consensus within the scientific community that complex, age-related decline requires equally complex, multi-pathway interventions.

Targeting the Frailty Epidemic Through Multi-Active Secretomes

At the heart of this longevity pivot is the urgent need to address sarcopenia—the involuntary loss of skeletal muscle mass and strength that affects virtually all individuals as they age. Sarcopenia is not merely a cosmetic issue; it is a primary driver of metabolic dysfunction, falls, hospitalization, and the loss of autonomy in older adults. Despite its universal prevalence and staggering economic toll, there are currently no approved pharmaceutical treatments capable of effectively attenuating this muscle loss or actively enhancing muscle regeneration.

The traditional drug development playbook has long favored single-target therapeutics, isolating a specific biological pathway and attempting to modulate it. However, aging and muscle atrophy are inherently complex, arising from the dysregulation of multiple overlapping cellular signaling networks. Immunis has bypassed the single-target orthodoxy by advancing IMM01-STEM, an investigational multi-active biologic.

IMM01-STEM is engineered using a proprietary stem cell secretome platform. Rather than administering live stem cells to patients—a process fraught with logistical, regulatory, and biological hurdles—the therapy utilizes a "cell-free" approach. It harvests the potent mixture of soluble immunomodulatory proteins, growth factors, and cytoskeletal remodeling molecules naturally released by partially differentiated human stem cells. By delivering this balanced cocktail of regenerative factors directly into the muscle, the biologic is designed to simultaneously stimulate multiple pathways involved in tissue repair, immune regulation, and metabolic enhancement.

“Living longer only represents progress if we can also preserve the strength and physical function that allow people to remain independent and engaged in their lives,” said Dr. Hans Keirstead, Chairman of Immunis. “Being selected as a semifinalist by the National Academy of Medicine is meaningful recognition of the progress we have made toward a different approach to healthy aging. Rather than simply managing the consequences of muscle decline, we are developing a multi-active biologic designed to restore muscle health and function. We believe regenerative medicine has the potential to fundamentally change what growing older looks like.”

Clinical Validation: Moving Beyond the Petri Dish

The transition from promising preclinical theory to human clinical efficacy is the graveyard of many biotechnology startups. However, the Irvine-based firm has successfully navigated this chasm, generating compelling human data that likely bolstered its position in the NAM competition.

In a completed Phase 1/2a clinical trial involving elderly individuals suffering from muscle atrophy associated with knee osteoarthritis, the biologic demonstrated a favorable safety profile with no serious adverse events reported. More importantly, early efficacy signals emerged. Patients receiving the treatment showed clinically meaningful improvements in gait speed during a standard six-minute walk test, alongside enhancements in quality-of-life metrics related to stiffness and physical function.

The clinical narrative has only strengthened with the company's ongoing Phase 2 trial, known as STEM-META. This double-blind, placebo-controlled study targets a particularly challenging demographic: obese seniors experiencing severe muscle loss and metabolic dysfunction. This condition, known as sarcopenic obesity, is a growing public health crisis.

Recent interim results from the Phase 2a portion of the trial revealed that patients treated with the secretome biologic experienced a remarkable 26 percent improvement in gait speed compared to those receiving a placebo. The absolute change in gait speed reached a gain of 0.12 meters per second at four weeks, and increased further to 0.16 meters per second at three months post-treatment. Geriatric specialists widely consider a 0.1 meter per second improvement as the threshold for a clinically meaningful enhancement in quality of life. Gait speed is not just a measure of walking; it is viewed by clinicians as a comprehensive biomarker of physiological reserve, predicting functional decline, hospitalization risk, and even mortality.

These robust clinical milestones have not gone unnoticed by the financial sector. The positive exploratory data triggered a Series B fundraising round earlier this year, providing the capital necessary to propel the therapy toward confirmatory Phase 2b trials expected to initiate by early 2028.

Inside the $36 Million Bet to Extend Healthspan

The rapid clinical advancement of this secretome technology underscores the critical role of structured innovation initiatives like the Healthy Longevity Global Competition. Launched by the National Academy of Medicine in 2019, the program was designed to comprehensively address the challenges of global population aging by catalyzing breakthrough research and building a broad ecosystem of support.

Over the past seven years, NAM and its international partners have disbursed more than $36 million across six Catalyst Award cycles. This decentralized funding model allowed the academy to cast a wide net, seeding 720 early-stage projects globally. By providing non-dilutive capital and institutional validation at the earliest stages of research, the program de-risked radical ideas that might have otherwise been ignored by traditional venture capital.

Immunis serves as a textbook case study for this philanthropic model. The company previously utilized a Healthy Longevity Catalyst Award to explore the fundamental potential of multi-active secretomes in reversing muscle atrophy. That initial validation and capital infusion helped bridge the gap between preclinical exploration and the robust human clinical trials now underway. The competition's structure effectively incubated the technology, allowing it to mature into a highly scalable intervention capable of addressing a global medical need.

The New Frontier of Longevity Economics

As the biotechnology landscape evolves, the intersection of longevity and lifestyle is becoming increasingly pronounced. The current cultural phenomenon surrounding GLP-1 weight-loss drugs has inadvertently highlighted the urgent need for muscle-preserving therapies. While popular metabolic drugs are highly effective at reducing fat, they frequently cause a simultaneous, significant loss of lean muscle mass. Industry analysts point out that secretome-based biologics could emerge as a vital complementary therapy, allowing patients to achieve metabolic health without sacrificing the physical strength required for daily living.

Ultimately, the quest for healthy longevity is evolving into an economic imperative. The global healthcare infrastructure is ill-equipped to handle the impending wave of frailty associated with an aging population. Preserving the mobility dividend—the economic and social value generated when older adults maintain their independence and avoid institutional care—is perhaps the most pressing challenge of the 21st century.

When the scientific community gathers in Washington, D.C. next week for the Healthy Longevity Global Innovator Summit, the announcement of the $1.5 million Grand Prize winner will serve as a capstone to a historic initiative. Regardless of which project takes the final podium, the elevation of multi-active regenerative therapies to the semifinalist stage confirms that the future of aging will not be defined by merely counting our years, but by fiercely protecting the strength required to live them.